Humanigen Raises Chances of Lenzilumab EUA With Severe COVID-19 Data
Executive Summary
Data on medRxiv showed a 90% improvement in likelihood of need for mechanical ventilation in the intent-to-treat population. The company plans a filing in Q2.
You may also be interested in...
Humanigen Data Show Success In High-Risk COVID-19 Population
Phase III results show benefit in cytokine-release syndrome, while other drugs for treating patients hospitalized with COVID-19 have produced mixed results.
GSK Antibody Appears Effective In Older COVID-19 Patients
With elderly patients disproportionately facing hospitalization and death from COVID-19, success in the clinic would create an important market for the drug.
Humanigen Takes Aim At IL-6 Inhibitors With CRS Drug Lenzilumab
Roche's Actemra is a major player in this space, but Humanigen is looking to take it on directly.